Related Experiment Video
Updated: Aug 17, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes,
Milad Rasouli1, Fatemeh Babaei2, Nadia Fallahhossein3
1The Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; School of Engineering Design and Innovation, The Pennsylvania State University, University Park, PA 16801, USA; Nova National School of Public Health, Nova University of Lisbon, Lisbon, Portugal.
Abstract:
Multidrug resistance (MDR) in colorectal cancer (CRC) arises from interacting tumour-cell, pharmacological and microenvironmental programmes that undermine both drug activity and delivery. Chemotherapy-associated MDR is the principal focus of this review, while resistance to targeted therapy and immunotherapy is considered where it directly affects delivery design or patient selection. Bioactive compounds can modulate several resistance pathways, but their translational value is constrained by poor solubility, instability, rapid metabolism and inadequate exposure at resistant lesions. This review critically examines when nanomedicine can make such mechanistic activity pharmacologically and translationally meaningful. We link resistance biology to delivery functions, evaluate bioactive chemosensitiser candidates against human exposure, compare major nanomedicine design strategies, and assess nano-bio interactions, repeat-dose safety, manufacturing and clinical positioning. Across the evidence, three limitations recur. First, concentrations associated with chemosensitisation for curcumin, resveratrol, epigallocatechin gallate and quercetin generally exceed measured human parent-analyte exposure. Second, many resistance claims rely on parental or poorly characterised models, whereas studies combining defined resistance provenance with functional mechanism and exposure confirmation remain uncommon. Third, human studies demonstrate feasibility, tissue exposure or treatment response, but not mechanism-specific reversal of CRC MDR by a bioactive compound or bioactive nanomedicine. Progress therefore depends less on adding new particle classes than on matching a necessary formulation function to a defined resistance or spatial barrier, quantifying active exposure in the relevant compartment, validating mechanism in appropriate models, and integrating repeat-dose safety, scalable manufacturing and biomarker-guided clinical development.
Insights
Nanomedicine can overcome multidrug resistance (MDR) in colorectal cancer (CRC) by improving drug delivery. However, challenges remain in matching nanomedicine function to resistance mechanisms and ensuring adequate human exposure and safety.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Multidrug resistance (MDR) in colorectal cancer (CRC) involves complex tumour, pharmacological, and microenvironmental factors hindering drug efficacy.
- While bioactive compounds show promise, their clinical utility is limited by poor pharmacokinetics and insufficient exposure at tumour sites.
- Existing research often uses inadequate models, complicating the translation of resistance reversal strategies.
Purpose of the Study:
- To critically evaluate the potential of nanomedicine to enhance the pharmacological and translational value of bioactive compounds in overcoming CRC MDR.
- To link resistance biology with drug delivery functions, assess bioactive chemosensitizers against human exposure data, and compare nanomedicine design strategies.
- To analyze nano-bio interactions, safety, manufacturing, and clinical positioning of nanomedicine for CRC treatment.
Main Methods:
- Review and synthesis of existing literature on nanomedicine, bioactive compounds, and CRC MDR.
- Evaluation of chemosensitizer candidates (e.g., curcumin, resveratrol) against human exposure levels.
- Comparison of different nanomedicine design strategies and assessment of their interaction with biological systems.
- Analysis of safety, manufacturing scalability, and clinical integration aspects.
Main Results:
- Many bioactive compounds show chemosensitizing effects only at concentrations exceeding measured human exposure.
- A frequent limitation is the reliance on poorly characterized models for resistance studies.
- Human studies confirm nanomedicine feasibility and exposure but lack definitive proof of mechanism-specific MDR reversal in CRC.
Conclusions:
- Translational success requires matching nanomedicine formulation to specific resistance or spatial barriers.
- Quantifying active exposure, validating mechanisms in appropriate models, and ensuring safety and manufacturability are crucial.
- Future progress hinges on integrated development, including biomarker-guided clinical trials, rather than solely on novel particle classes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...